Loading...
NPI 1538144910 · Burlington, NC · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Laboratory Corporation Of America Holdings is a clinical medical laboratory provider located in Burlington, North Carolina. This profile covers 658 Medicare and 747 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Laboratory Corporation Of America Holdings |
| Address | 1447 York Ct |
| City | Burlington |
| State | NC |
| ZIP | 27215 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | December 8, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $1.4B |
| Medicare | $214.6M |
LABORATORY CORPORATION OF AMERICA HOLDINGS is a high-volume clinical reference laboratory: its Medicare top CPT codes are concentrated in core clinical chemistry, hematology, endocrinology, and infectious/drug testing (notably 80053, 80061, 85025, 84443, 82306, and multiple G048*/80307 codes). The mix of comprehensive metabolic panels, lipid panels, CBCs, TSH, vitamin D, and both presumptive and definitive drug testing indicates an operation set up for large-scale, centralized specimen processing and high-throughput automated analysis across broad outpatient testing needs.
Revenue concentration on Medicare is meaningful but not extreme: the precomputed top-3 Medicare CPT/HCPCS codes account for 30.3% of this provider's total Medicare revenue, showing that a relatively small set of common clinical panels and procedures drive a large share of Medicare dollars while a long tail of other tests provides the remainder. On Medicaid the top-3 codes account for 31.4% of total Medicaid revenue, indicating a similar concentration pattern across payers where a handful of high-volume tests dominate receipts.
On scale, Medicaid receipts substantially exceed Medicare for this provider: total Medicare revenue is $214.6M while total Medicaid revenue is $1.44B, so Medicaid is by far the larger payer relationship in dollar terms. This profile makes the entity functionally Medicaid-focused from a revenue perspective while still maintaining significant Medicare activity.
LABORATORY CORPORATION OF AMERICA HOLDINGS is a dominant national player on many Medicare codes and the clear market leader in-state on most Medicaid codes. Multiple Medicare codes (for example 80053, 36415, 80061, G0483, 84443, 82306, 85025, 83036) are reported as rank #1 nationally and 100th percentile (described in the data as "extreme outlier"), and an even larger set of Medicaid codes (U0003, 87491, 87798, 87591, , , etc.) are rank #1 in-state at the 100th percentile. This combination signals a commanding market share in both national Medicare volumes for selected codes and dominant statewide market share for Medicaid testing.
The provider is an outlier on many specific tests, which signals both scale and specialization: individual codes are labeled as "extreme outlier" or "notably above typical" in the data (examples include Medicare 80053, 36415, 80061 and Medicaid U0003, 87491, 87798). Where definitive drug testing codes appear (G0483, G0481, G0480) the entity ranks at or near the top nationally and within-state, reflecting unusually large-volume drug-testing capabilities including high-complexity, multi-class definitive assays.
COVID-19 and infectious disease testing are material drivers of Medicaid revenue in-state: U0003 alone accounts for $154.7M and 15.3% of the provider's total Medicaid revenue and ranks #1 in-state (100th percentile, extreme outlier), and related infectious NAAT codes (e.g., 87491, 87591, 87798, 87801) together make up large Medicaid shares. This suggests a major public-health and screening role in Medicaid populations during the reporting period.
The lab's service breadth includes high-cost specialty molecular and genomic panels as well as routine screening: Medicaid shows large revenue lines for high-cost codes such as 81420 ($44.7M) and 81220 ($22.2M), while Medicare includes algorithmic or RA biomarker panel 81490 ($1.8M). Presence of both high-throughput infectious assays and expensive genomic panels signals an operation that spans from mass screening to higher-complexity specialized testing.
Operational tenure supports established scale: the NPI was enumerated on 2005-12-08 (~21 years ago), indicating long-standing participation in Medicare/Medicaid and time to build the large national and in-state volumes observed across many codes. That history is consistent with the provider's role as a major centralized laboratory processing broad test volumes for payers and clinicians.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
658 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 1,492,280 | $10 | $14.9M |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 1,778,420 | $10 | $14.2M |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 1,052,280 | $10 | $13.7M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 53,480 | $240 | $12.8M |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 764,870 | $20 | $12.2M |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 378,260 | $30 | $11M |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 1,141,600 | $10 | $9.1M |
| 83036 | Sugar in the bloodstream can get attached to the hemoglobin in red blood cells. Once the sugar is attached, it stays there for the lifetime of the red blood cell (around 120 days or over 3 months).… | 673,510 | $10 | $6.7M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 98,430 | $60 | $6M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 30,050 | $150 | $4.6M |
Showing 1–10 of 658
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 658 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
658 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87999 | 1 | 10 | 5,330 | $240 | $1.3M |
| 81490 | 1 | 10 | 1,080 | $820 | $890.6K |
| 81479 | 2 | 10 | 880 | $530 | $835.6K |
| U0003 | 2 | 10 | 90 | $70 | $463.6K |
| 83704 | 1 | 10 | 290 | $30 | $379.7K |
| 87497 | 1 | 10 | 9,000 | $40 | $373.7K |
| 87536 | 1 | 10 | 60 | $80 | $328.6K |
| G0483 | 1 | 80 | 70 | $240 | $291.1K |
| 81374 | 2 | 10 | 3,740 | $70 | $272.1K |
| P9603 | 6 | 10 | 66,050 | $1 | $236.5K |
Showing 1–10 of 658
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
747 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1,983,530 | $80 | $154.7M |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 3,981,820 | $20 | $83.6M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 2,408,210 | $30 | $79.5M |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 3,971,410 | $20 | $79.4M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 2,203,810 | $40 | $77.1M |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 1,359,690 | $40 | $50.3M |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 2,757,290 | $20 | $49.6M |
| 81420 | The lab analyst performs a genomic sequence analysis panel to evaluate circulating cell free fetal DNA in maternal blood for genetic sequences of at least the genes on chromosomes 13, 18, and 21,… | 102,860 | $440 | $44.7M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 550,210 | $70 | $39.1M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 683,860 | $50 | $33.5M |
Showing 1–10 of 747
How this provider's Medicaid billing volume and revenue compare to other North Carolina providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. North Carolina median
747 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 81420 | The lab analyst performs a genomic sequence analysis panel to evaluate circulating cell free fetal DNA in maternal blood for genetic sequences of at least the genes on chromosomes 13, 18, and 21,… | 2 | 20 | 240 | $400 | $13.6M |
| 81220 | The lab analyst performs the technical lab test to detect the presence of changes in the gene for cystic fibrosis transmembrane conductance regulator, also known as CFTR. The test evaluates the CFTR… | 2 | 30 | 170 | $260 | $2.6M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1 | 160 | 840 | $70 | $2.3M |
| 81229 | The lab analyst performs the technical lab test using comparative genomic hybridization (CGH) microarray, also referred to as chromosomal microarray (CMA) or molecular karyotype performed by… | 4 | 10 | 680 | $480 | $1.9M |
| 87902 | The lab analyst performs the technical lab test to analyze the specific genotype by nucleic acid of a specimen containing hepatitis C virus. | 1 | 10 | 1,360 | $150 | $1.8M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 110 | 1,450 | $110 | $1.7M |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 1 | 40 | 480 | $40 | $1.4M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 1 | 80 | 420 | $30 | $1.2M |
| 87901 | The lab analyst performs the technical lab test to analyze the patient specimen, typically serum, for the reverse transcriptase and protease regions of the specific genotype of the virus causing the… | 1 | 10 | 260 | $150 | $977.9K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 60 | 1,640 | $100 | $940.2K |
Showing 1–10 of 747
Other providers in the same ZIP code as Laboratory Corporation Of America Holdings, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.